Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
December 11 2018 - 6:30AM
Tetra Bio-Pharma Inc. (“
Tetra” or
“
TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a
leader in cannabinoid-based drug discovery and development confirms
its non-exclusive supply agreement for GMP-Grade THC with
U.S.-based Rhodes Technologies Inc. The supply will be used for
several drug development activities including Tetra’s
cannabinoid-derived products PPP002, PPP003, and PPP004, as well as
for discovery phase projects. This is additional to having a
supply agreement with True North Cannabis Inc. for CBD from
hemp which was necessary to meeting the demand associated with the
Genacol Corporation transaction.
“With a robust development
pipeline, it is essential for Tetra to have a reliable, API supply
to support our expanding needs and avoid product shortages,” said
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Our
agreement with Rhodes is predicated on their long history and
expertise in the production and sale of active chemical
ingredients, particularly in the area of pain management. In
terms of CBD, our suppliers are selected based on their ability to
provide us with both quality (GMP Pharmaceutical Grade) and
volume. Tetra is always mindful of the need to have
consistent supply as well as back-ups for each of the products
under development.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB:
TBPMF) is a biopharmaceutical leader in cannabinoid-based drug
discovery and development with a Health Canada approved,
and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. The Company has several subsidiaries engaged
in the development of an advanced and growing pipeline of Bio
Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the ability to
obtain orphan drug status, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
For
further information, please contact Tetra Bio-Pharma
Inc. |
Robert
(Bob) Bechard
|
Executive
Vice President, Corporate Development and Licensing |
514-817-2514 |
Investors@tetrabiopharma.com |
|
|
Media
Contact |
|
energi PR |
|
Carol Levine |
Stephanie
Engel |
Carol.Levine@energipr.com |
stephanie.engel@energipr.com |
514-288-8500 ext.
226 |
416-425-9143 ext.
209 |
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Apr 2023 to Apr 2024